



David Iser
Marno Ryan

Fatty liver disease

A practical guide for GPs

Background

Non-alcoholic fatty liver disease (NAFLD), encompassing both simple steatosis and non-alcoholic steato-hepatitis (NASH), is the most common cause of liver disease in Australia. Non-alcoholic fatty liver disease needs to be considered in the context of the metabolic syndrome, as cardiovascular disease will account for much of the mortality associated with NAFLD.

Objective

To provide an approach to the identification of NAFLD in general practice, the distinction between simple steatosis and NASH, and the management of these two conditions.

Discussion

Non-alcoholic steato-hepatitis is more common in the presence of diabetes, obesity, older age and increased inflammation, and is more likely to progress to cirrhosis. Cirrhosis may be complicated by hepatocellular carcinoma or liver failure. Hepatocellular carcinoma has also been described in NASH without cirrhosis. Assessment and treatment of features of the metabolic syndrome may reduce associated cardiovascular mortality. Numerous agents have been evaluated, but weight loss remains the only effective treatment for NAFLD.

Keywords

liver diseases; fatty liver



First described in 1980,¹ non-alcoholic fatty liver disease (NAFLD) is now the most common cause of liver disease in industrialised countries.² Non-alcoholic fatty liver disease includes both non-alcoholic steato-hepatitis (NASH), involving lobular inflammation and fibrosis, and simple steatosis (non-NASH). This distinction is important, as simple steatosis is unlikely to lead to liver related complications, whereas NASH may lead to increased fibrosis and cirrhosis, and its complications (*Figure 1*). The difficulty lies in trying to decide whether raised liver functions tests (LFTs) are due to simple steatosis, NASH without fibrosis, NASH with severe fibrosis or cirrhosis, or another cause of hepatitis altogether.

Epidemiology

The prevalence of NAFLD is estimated to be approximately 30% of adults in developed countries such as Australia and the United States, depending on definition and detection methods.³ However, NAFLD is also becoming increasingly common in Asia (countries previously thought to be at low risk of NAFLD), where a prevalence of up to 15% has been reported in China.⁴

Natural history

Simple steatosis appears to be a relatively benign condition, although it may progress to NASH over time. Cardiovascular disease is the major cause of death in patients with NAFLD;⁵ NAFLD alone is associated with a slightly higher overall mortality. However, when NAFLD occurs in the presence of other features of the metabolic syndrome (MetSy), mortality doubles.⁶ The MetSy is a clustering of cardiovascular risk factors related to reduced insulin sensitivity. Diagnostic criteria for the syndrome include:⁷

- elevated serum triglycerides (TG)
- lowered serum high-density lipoprotein cholesterol (HDL-C)
- impaired glucose tolerance
- central adiposity
- hypertension.

Although NAFLD is not officially included in the definition of the MetSy, it commonly co-exists with features of this syndrome.

In addition to its association with cardiovascular complications, NAFLD can lead to liver related morbidity and mortality. The risk of developing cirrhosis is higher in the presence of NASH, which is more likely in the presence of the following features:

- type 2 diabetes mellitus (T2DM)
- obesity (body mass index [BMI] >30 kg/m²)




Figure 1. The natural history of non-alcoholic fatty liver disease

- age more than 50 years
- serum aminotransferases (ALT or AST) more than two times the upper limit of normal.

Non-alcoholic steato-hepatitis cirrhosis probably accounts for the vast majority of what was previously described as ‘cryptogenic cirrhosis’. In one series, 70% of patients with cryptogenic cirrhosis had risk factors for NAFLD.⁸ In the US, NASH is an increasingly common indication for liver transplantation.^{9,10} In the setting of cirrhosis from NASH, the risk of developing hepatocellular carcinoma (HCC) is between 2.4% over 7 years, and 12.8% over 3 years,¹¹ compared to 21% over 10 years for hepatitis C cirrhosis.¹² Hepatocellular carcinoma has also been reported in NASH without cirrhosis, particularly in association with the MetSy.¹³

Identifying NAFLD and NASH in general practice

The most common presentation of NAFLD will be incidental finding of abnormal LFTs. Typical findings in NAFLD are raised ALT and AST, with a preserved ALT: AST ratio of 1.5, raised gamma glutamyl transferase (GGT) and, occasionally, raised alkaline phosphatase (ALP). These findings commonly occur in the setting of features of the MetSy.

There are several features on examination and laboratory values that should raise suspicion of cirrhosis, such as spider naevi, low or falling platelets, low albumin or reversal in ALT:AST ratio (where AST exceeds ALT), before the features of portal hypertension and decompensation become obvious.

Apart from excluding excess alcohol consumption as a potential cause, there are several other important causes of raised ALT that

need to be excluded, such as viral hepatitis, autoimmune hepatitis, haemochromatosis, thyroid disease and coeliac disease (Table 1).

Diagnostic assessment of NAFLD

A definitive diagnosis of NAFLD depends on three factors:

- evidence of fatty infiltration from either imaging (ultrasound, magnetic resonance imaging [MRI]) or histology (liver biopsy)
- exclusion of significant alcohol consumption
- exclusion of other causes of hepatic steatosis (eg. medications, surgery, metabolic disorders).

Confirming hepatic fatty infiltration using ultrasound is important. Specificity is high (95%), but the sensitivity of ultrasound for detecting fatty infiltration is lower (85%).¹⁴ Ultrasound is also useful to look for signs of cirrhosis, such as irregular liver edge, but has a sensitivity of only 43–74% (specificity is slightly higher at 54–89%).¹⁵ Signs of cirrhotic complications are also important, eg. signs of portal hypertension (splenomegaly, increased portal vein size, varices) or other complications such as HCC, portal vein thrombosis, or ascites.

The risk of fibrosis and progressive liver disease in NAFLD increases with severity of insulin resistance. In the absence of simple available clinical measurements of insulin resistance, the number of MetSy features present can be used to estimate risk of insulin resistance. The presence of three or more features of the syndrome, especially if these include central adiposity and T2DM, are predictive of the presence of NASH rather than simple steatosis. In addition, family history plays a role: an individual with a first degree relative with T2DM has a 90% chance of developing T2DM, and therefore NASH.¹⁶ Central adiposity can be assessed using waist circumference measured at the narrowest point mid-way between the lowest rib and the iliac crest at the end of expiration with the patient standing.

Staging liver disease and detecting cirrhosis is the most important aspect of assessing fatty liver disease. However, it is also difficult and error prone. The traditional gold standard in assessing liver disease is liver biopsy. However, biopsy has unfavourable cost, safety, availability, sampling error, inter-observer variability and patient acceptance. Liver biopsy may be considered where cirrhosis is suspected, or where an alternative diagnosis is considered. At this stage, referral to a gastroenterologist is also suggested.

Non-invasive tools for estimating the degree of fibrosis include transient elastography (FibroScan®), acoustic radiation force impulse (ARFI), and non-invasive biomarker algorithms such as NAFLD Fibrosis Score, FibroTest and Hepascore. However, their use in clinical practice is still being evaluated.

Management of NAFLD

Cardiovascular risk factors and lifestyle modification

The cornerstone to managing NAFLD is achieving weight control and reduction in cardiovascular risk factors such as smoking, diabetes, hypertension and dyslipidaemia. This may include referral to a dietician,



Table 1. What to consider and how to exclude differential diagnoses

Consideration	Test
Excess alcohol consumption	Careful, corroborative history
Chronic hepatitis B	HBsAg, anti-HBs, anti-HBc
Chronic hepatitis C	Hepatitis C antibody
Autoimmune hepatitis	Anti-nuclear antibody (ANA) Anti-smooth-muscle antibody (ASMA) Anti-mitochondrial antibody (AMA)
Haemochromatosis	Iron studies
Thyroid disease	Thyroid function tests
Coeliac disease	Coeliac antibodies (usually deamidated antigliadin antibody, tissue transglutaminase, total IgA level)
Medications	History of amiodarone, anticonvulsants, methotrexate, tamoxifen, synthetic oestrogens, corticosteroids, HIV therapy, perhexiline

endocrinologist or cardiologist. Treatment of associated dyslipidaemia is appropriate with either HMGCo-A reductase inhibitors ('statins') or fibrates where required. Moderate elevations in liver enzymes due to the use of statins should be tolerated and treatment continued.¹⁷ However, severe elevations more than 10 times the upper limit of normal should prompt cessation of the medication and reassessment.

Dietary manipulation, such as the adoption of a Mediterranean-type diet, has shown promise. The most important feature appears to be caloric reduction. Where diet and exercise are unsuccessful in achieving weight reduction, bariatric surgery may be considered.

Novel treatments

Various therapeutic agents have shown some promise in the management of NAFLD.^{18–22} However, weight loss remains the only therapy with proven benefit and safety.^{23–27}

What follow up should be performed?

A pragmatic approach to the investigation and management of NAFLD is presented in *Figure 2*.²⁸ Normalisation of LFTs associated with mild weight loss may be an encouraging sign that the disease activity is driven by NAFLD. However, it is important to stage the disease initially (with ultrasound and histology if appropriate). The presence of normal LFTs does not exclude underlying cirrhosis, nor does a 'non-cirrhotic' ultrasound. Monitoring full blood examination (FBE), LFTs, International Normalised Ratio (INR), blood pressure and lipid profile every 6 months is a reasonable approach.

When to refer for specialist management

Referral for specialist management should be undertaken whenever there is a suspicion of severe fibrosis or cirrhosis, whether at initial assessment or at any time during monitoring.

Key points

- Non-alcoholic fatty liver disease is increasingly common, and will have a significant impact on morbidity and mortality on a growing number of Australians.




Figure 2. Algorithm for management of suspected NAFLD

- NAFLD should be considered when abnormal LFTs are found, particularly in the presence of features of the MetSy.
- Weight reduction via caloric restriction and regular exercise are important, and no medications can currently be recommended as specific therapy.
- General practitioners are vital in identifying patients at risk of NAFLD, and encouraging initiation and maintenance of appropriate lifestyle changes.



Further reading

- The diagnosis and management of NAFLD: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. Available at www.aasld.org/practiceguidelines/Documents/NonalcoholicFattyLiverDisease2012_25762_ftp.pdf
- Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of NAFLD in the Asia Pacific region: Executive summary. *J Gastroenterol Hepatol* 2007;22:775–7. Available at www.medscape.com/viewarticle/559335_1
- Farrell GC, editor. Fatty liver disease: When to suspect it? What to do about it? GESA guidelines. Available at www.gesa.org.au/files/editor_upload/File/Professional/Fatty-Liver-1st-Edition.pdf
- Ratziu V, Bellentini S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol* 2010;53:372–84. Available at <http://f.i-md.com/medinfo/material/714/4e113707e4b02d0c1e8d2714/494B559E82E5F1F07D8015701B2ABFC6.pdf>
- World Gastroenterology Global Guidelines: NAFLD and NASH. Available at www.worldgastroenterology.org/assets/export/userfiles/2012_NASH%20and%20NAFLD_Final_long.pdf.

Authors

David Iser MBBS(Hons), BMedSc, FRACP, PhD, is a gastroenterologist, Department of Gastroenterology, St Vincent's Hospital, Melbourne and Infectious Diseases Unit, The Alfred Hospital, Melbourne, Victoria. david.iser@svhm.org.au

Marno Ryan MBBS(Hons), FRACP, MD, is a gastroenterologist, Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria.

Competing interests: None.

Provenance and peer review: Commissioned; externally peer reviewed.

References

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980;55:434–8.
2. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver disease in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol* 2011;9:524–30.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40:1387–95.
4. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. *J Hepatol* 2005;43:508–14.
5. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. *J Hepatol* 2008;49:608–12.
6. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* 2007;49:403.
7. The IDF consensus worldwide definition of the metabolic syndrome. Available at www.idf.org/webdata/docs/MetS_def_update2006.pdf [Accessed 16 February 2013].
8. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. *Hepatology* 1999;29:664.
9. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology* 2002;123:134–40.
10. Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. *Liver Transpl* 2011;18:29–37.
11. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clin Gastroenterol Hepatol* 2012;10:1342.
12. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatitis fibrosis. *JAMA* 2012;308:2584–93.
13. Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. *Int J Cancer* 2011;128:2436–43.
14. Hemaiez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology* 2011;54:1082–90.
15. Choong CC, Venkatesh SK, Siew EP. Accuracy of routine clinical ultrasound for staging of liver fibrosis. *J Clin Imagin Sci* 2012;2:58.
16. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 2003;37:917–23.
17. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet* 2010;376:1916.
18. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2010;32:1211–21.
19. Boettcher E, Csasko G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2012;35:66.
20. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology* 2010;52:79.
21. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. *Hepatology* 2011;54:1610.
22. Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol* 2012;56:944.
23. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. *Hepatology* 2004;39:1647.
24. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. *Gut* 2004;53:413.
25. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010;51:121.
26. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol* 2012;57:157.
27. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. *Cochrane Database Syst Rev* 2010;20:CD007340.
28. Farrell G, et al. Fatty liver disease. GESA guidelines, 2007. Available at www.gesa.org.au/files/editor_upload/File/Professional/Fatty-Liver-1st-Edition.pdf [Accessed 7 June 2013].

correspondence afp@racgp.org.au